SCHEMBL12458982

SCHEMBL12458982

O=C(Nc1ccc(CC2CCN(Cc3ccc(C(O)(C(F)(F)F)C(F)(F)F)cc3)CC2)cc1)N1CCCCC1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HIF1A Q16665 1/20 0.56
EPAS1 Q99814 1/20 0.56
FAAH O00519 4/20 0.52
PRKAB2 O43741 6/20 0.52
PRKAG1 P54619 6/20 0.52
PRKAA2 P54646 6/20 0.52
PRKAA1 Q13131 6/20 0.52
PRKAG3 Q9UGI9 6/20 0.52
PRKAG2 Q9UGJ0 6/20 0.52
PRKAB1 Q9Y478 6/20 0.52
RORC P51449 1/20 0.50
CCR3 P51677 2/20 0.48
TP53 P04637 1/20 0.47
MAPT P10636 1/20 0.47
KMT2A Q03164 3/20 0.47
MEN1 O00255 2/20 0.47
LMNA P02545 1/20 0.47
NPC1 O15118 1/20 0.46
RAB9A P51151 1/20 0.46
DNMT1 P26358 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1870500 0.84 HIF1A (0.59) HIF1AEPAS1RORCCCR3KMT2A
SCHEMBL1869907 0.84 CCR3 (0.58) HIF1AEPAS1RORCCCR3KMT2A
SCHEMBL1862776 0.83 HIF1A (0.71) HIF1AEPAS1RORCCCR3KMT2A
SCHEMBL1869122 0.83 HIF1A (0.57) HIF1AEPAS1RORCCCR3TP53
SCHEMBL12274057 0.82 SIGMAR1 (0.57) HIF1AEPAS1RORCCCR3KMT2A
SCHEMBL1873273 0.82 CCR3 (0.58) HIF1AEPAS1RORCCCR3KMT2A
SCHEMBL1871271 0.82 HIF1A (0.55) HIF1AEPAS1RORCCCR3TP53
SCHEMBL12076505 0.81 HIF1A (0.51) HIF1AEPAS1RORCCCR3KMT2A
SCHEMBL1872044 0.81 HIF1A (0.55) HIF1AEPAS1RORCCCR3KMT2A
SCHEMBL1865420 0.80 HIF1A (0.58) HIF1AEPAS1RORCCCR3KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9108939-B2 (1, 1, 1,3,3,3-hexafluoro-2 hydroxypropan-2-yl) phenyl derivative, pharmaceutical compositions thereof and their use for the treatment of atherosclerosis MERCK SHARP & DOHME B.V. (NL) 2015-08-18 US disclosed
US-9108939-B2 (1, 1, 1,3,3,3-hexafluoro-2 hydroxypropan-2-yl) phenyl derivative, pharmaceutical compositions thereof and their use for the treatment of atherosclerosis MERCK SHARP & DOHME B.V. (NL) 2015-08-18 US disclosed
EP-2493855-B1 (1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl derivatives, pharmaceutical compositions thereof and their use for the treatment of atherosclerosis MERCK SHARP & DOHME (NL) 2014-02-26 EP disclosed
US-20120238574-A1 (1, 1, 1,3,3,3 -HEXAFLUORO-2 HYDROXYPROPAN- 2 -YL) PHENYL DERIVATIVE, PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR USE FOR THE TREATMENT OF ATHEROSCLEROSIS N.V. ORGANON (NL) 2012-09-20 US disclosed
US-20120238574-A1 (1, 1, 1,3,3,3 -HEXAFLUORO-2 HYDROXYPROPAN- 2 -YL) PHENYL DERIVATIVE, PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR USE FOR THE TREATMENT OF ATHEROSCLEROSIS N.V. ORGANON (NL) 2012-09-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120238574-A1 (1, 1, 1,3,3,3 -HEXAFLUORO-2 HYDROXYPROPAN- 2 -YL) PHENYL DERIVATIVE, PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR USE FOR THE TREATMENT OF ATHEROSCLEROSIS TGFB1, FPR1, TGFB2 HIF1A 104/4885EPAS1 204/4885FAAH 431/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.